Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Glioblastoma 2Choriocarcinoma 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Trophoblastic Tumor, Placental Site 1Ovarian Neoplasms 1Liver Neoplasms 1Glioma 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Sunitinib 64Nivolumab 54Sorafenib 38Bevacizumab 35Axitinib 35pembrolizumab 34Everolimus 30cabozantinib 29pazopanib 26aldesleukin 26Ipilimumab 23Interleukin-2 19Specimen Handling 17Magnetic Resonance Spectroscopy 17Gemcitabine 17lenvatinib 16Interferon-alpha 15Interferon alpha-2 13Radiosurgery 12Cyclophosphamide 12fludarabine phosphate 11atezolizumab 10durvalumab 8Introns 8Erlotinib Hydrochloride 8Biopsy 8temsirolimus 7avelumab 7Radiotherapy 7Capecitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Renal Cell × carotuximab × Clear all
NCT01727089 2018-08-28

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
59 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡